GH Research (GHRS) Competitors

GH Research logo
$18.27 -0.48 (-2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$19.38 +1.11 (+6.07%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GHRS vs. DFTX, LQDA, TARS, OGN, and ARQT

Should you buy GH Research stock or one of its competitors? GH Research's main competitors and comparable companies include Definium Therapeutics (DFTX), Liquidia (LQDA), Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GH Research compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

GH Research's return on equity of -20.86% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
GH Research N/A -20.86%-20.12%

In the previous week, Definium Therapeutics had 6 more articles in the media than GH Research. MarketBeat recorded 17 mentions for Definium Therapeutics and 11 mentions for GH Research. GH Research's average media sentiment score of 0.59 beat Definium Therapeutics' score of 0.50 indicating that GH Research is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GH Research
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
GH ResearchN/AN/A-$48.26M-$0.95N/A

Definium Therapeutics presently has a consensus price target of $66.24, suggesting a potential upside of 119.61%. GH Research has a consensus price target of $44.36, suggesting a potential upside of 136.61%. Given GH Research's higher possible upside, analysts plainly believe GH Research is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95
GH Research
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Definium Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Definium Therapeutics and GH Research tied by winning 7 of the 14 factors compared between the two stocks.

How does GH Research compare to Liquidia?

GH Research (NASDAQ:GHRS) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

GH Research currently has a consensus target price of $44.36, suggesting a potential upside of 136.61%. Liquidia has a consensus target price of $75.23, suggesting a potential upside of 33.46%. Given GH Research's stronger consensus rating and higher probable upside, research analysts plainly believe GH Research is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Liquidia
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50

GH Research has a net margin of 0.00% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat GH Research's return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -20.86% -20.12%
Liquidia -15.15%264.65%44.19%

In the previous week, Liquidia had 24 more articles in the media than GH Research. MarketBeat recorded 35 mentions for Liquidia and 11 mentions for GH Research. Liquidia's average media sentiment score of 0.60 beat GH Research's score of 0.59 indicating that Liquidia is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GH Research
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Liquidia
8 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

GH Research has higher earnings, but lower revenue than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$48.26M-$0.95N/A
Liquidia$158.32M32.08-$68.92M-$1.23N/A

56.9% of GH Research shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Summary

Liquidia beats GH Research on 9 of the 16 factors compared between the two stocks.

How does GH Research compare to Tarsus Pharmaceuticals?

GH Research (NASDAQ:GHRS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

GH Research has higher earnings, but lower revenue than Tarsus Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$48.26M-$0.95N/A
Tarsus Pharmaceuticals$451.36M8.60-$66.42M-$15.19N/A

In the previous week, GH Research had 10 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for GH Research and 1 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.79 beat GH Research's score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
GH Research Positive
Tarsus Pharmaceuticals Very Positive

GH Research has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -102.93%. GH Research's return on equity of -20.86% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -20.86% -20.12%
Tarsus Pharmaceuticals -102.93%-24.51%-12.40%

GH Research currently has a consensus price target of $44.36, suggesting a potential upside of 136.61%. Tarsus Pharmaceuticals has a consensus price target of $104.57, suggesting a potential upside of 32.91%. Given GH Research's higher possible upside, equities analysts plainly believe GH Research is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Tarsus Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

56.9% of GH Research shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

GH Research and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does GH Research compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Organon & Co. has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, GH Research has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Organon & Co. currently has a consensus price target of $12.00, indicating a potential downside of 13.70%. GH Research has a consensus price target of $44.36, indicating a potential upside of 136.61%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
GH Research
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.59$187M$0.7618.30
GH ResearchN/AN/A-$48.26M-$0.95N/A

In the previous week, GH Research had 7 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for GH Research and 4 mentions for Organon & Co.. GH Research's average media sentiment score of 0.59 beat Organon & Co.'s score of 0.55 indicating that GH Research is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GH Research
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Organon & Co. has a net margin of 3.49% compared to GH Research's net margin of 0.00%. Organon & Co.'s return on equity of 82.06% beat GH Research's return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.49% 82.06% 6.03%
GH Research N/A -20.86%-20.12%

Summary

Organon & Co. beats GH Research on 10 of the 15 factors compared between the two stocks.

How does GH Research compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

56.9% of GH Research shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arcutis Biotherapeutics presently has a consensus target price of $39.75, suggesting a potential upside of 46.41%. GH Research has a consensus target price of $44.36, suggesting a potential upside of 136.61%. Given GH Research's higher possible upside, analysts plainly believe GH Research is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
GH Research
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, GH Research had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 11 mentions for GH Research and 6 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.75 beat GH Research's score of 0.59 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GH Research
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Arcutis Biotherapeutics has a net margin of 5.88% compared to GH Research's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 14.18% beat GH Research's return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics5.88% 14.18% 6.28%
GH Research N/A -20.86%-20.12%

Arcutis Biotherapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M9.13-$16.14M$0.21129.29
GH ResearchN/AN/A-$48.26M-$0.95N/A

Arcutis Biotherapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Summary

Arcutis Biotherapeutics beats GH Research on 11 of the 15 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GHRS vs. The Competition

MetricGH ResearchPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.25B$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-19.2329.4134.1729.85
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book4.055.114.373.66
Net Income-$48.26M$2.88B$3.52B$392.27M
7 Day Performance-6.60%-4.11%-5.47%-4.72%
1 Month Performance0.66%-5.09%-4.58%-7.14%
1 Year Performance29.57%-7.45%-1.79%-7.51%

GH Research Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GHRS
GH Research
2.1592 of 5 stars
$18.27
-2.6%
$43.45
+137.8%
+33.9%$1.25BN/AN/A73
DFTX
Definium Therapeutics
3.117 of 5 stars
$34.18
-3.4%
$66.24
+93.8%
+165.7%$4.59BN/AN/A40
LQDA
Liquidia
3.1237 of 5 stars
$51.19
+6.9%
$74.15
+44.9%
+101.0%$4.54B$158.32M37.00216
TARS
Tarsus Pharmaceuticals
3.1915 of 5 stars
$74.30
+4.9%
$104.57
+40.7%
+7.9%$3.67B$451.36MN/A370
OGN
Organon & Co.
1.5164 of 5 stars
$13.88
+0.2%
$11.40
-17.8%
+84.3%$3.64B$6.22B18.2410,000

Related Companies and Tools


This page (NASDAQ:GHRS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners